Best Dow Dividend Companies To Own For 2014

LONDON -- A popular way to dig out reasonably priced stocks with robust growth potential is through the "Growth At A Reasonable Price," or�GARP, strategy.

This theory uses the price-to-earnings to growth (PEG) ratio to show how a share's price weighs up in relation to its near-term growth prospects -- a reading below one is generally considered decent value for money.

Today, I am looking at�Tesco� (LSE: TSCO  ) (NASDAQOTH: TSCDY  ) to see how it measures up.

What are�Tesco's earnings expected to do?

Metric� 2014 2015 EPS Growth 1% 5% P/E Ratio 10.6 10.1 PEG Ratio 15.9 2.1

Source: Digital Look.

Tesco is expected to recover from last year's 11% earnings per share dip with a slight recovery in the year ending March 2014. And City analysts expect earnings to enjoy a sizable bounce-back in 2015.

Hot Valued Companies To Invest In 2015: Barratt Developments PLC (BDEV)

Barratt Developments PLC is a holding company. The Company�� principal activities consists of acquiring and developing land, planning, designing and constructing residential property developments and selling the homes it builds. The Company operates in two segments: housebuilding and commercial developments. The Company operates across a spectrum of the market from flats to family homes and urban regeneration schemes. The Company also has a focused commercial developments business. The Company builds a range of homes ranging from those for first-time buyers, to family homes, to high-rise flats and affordable housing. The Company�� housebuilding business trades under the Barratt Homes, David Wilson Homes and Ward Homes brands. The Company�� subsidiaries include BDW Trading Limited, BDW North Scotland Limited, David Wilson Homes Limited and Wilson Bowden Developments Limited. Advisors' Opinion:

• [By Inyoung Hwang]

  U.K. homebuilders declined as increasing bond yields spurred concern rising interest rates may hinder the housing recovery. Barratt Developments Plc (BDEV) sank 7.4 percent, Persimmon Plc fell 3.6 percent and Taylor Wimpey Plc lost 3.7 percent.

Best Dow Dividend Companies To Own For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By Keith Speights]

  Currently, the top 10 stocks in which the ETF is invested comprise more than 55% of total assets. Sure, there are some speculative names included in the full list of holdings. However, the largest stakes are in big biotechs with long track records, like Gilead Sciences (NASDAQ: GILD  ) , Celgene (NASDAQ: CELG  ) , Amgen (NASDAQ: AMGN  ) , and Biogen Idec (NASDAQ: BIIB  ) . These top four holdings make up almost one-third of the ETF's total assets.

Best Dow Dividend Companies To Own For 2014: Nexans SA (NEX)

Nexans SA is a French company engaged in the cable industry. It provides copper and fiber-optic cables and cabling systems to the Energy Infrastructure, Industry, Building and Local Area Network (LAN) markets. It operates under three segments: Energy, Telecom and Electrical Wires and has six main product lines: indoor cabling, which includes rugged industrial, fire-performance and standard domestic cables; industrial cabling, which comprises a variety of cables for the automotive, aerospace and defense industries, among others; power network cabling, which offers low, medium and high-voltage cables; telecom network cabling that includes a range of copper and optical fiber cables and associated interconnect solutions and cable maker supply, which includes the provision of conductors and superconductive materials for making cables. The LAN Segment provides cables for business networks and offers integrated solutions combining cables, connectors, administration and security. Advisors' Opinion:

• [By Michael Lewis]

  Bloomberg via Getty Images William 'Bill' Ackman founder and CEO of Pershing Square Capital Management (left) Daniel Loeb, founder and CEO of Third Point: Two activist investors taking big positions in large public companies and demand even bigger changes. Is activist investing a force for good when it comes to shareholders? Recent events, namely the Bill Ackman-J.C. Penney (JCP) debacle, have left investors and analysts tired of the outspoken hedge-funders of the world. There are, of course, plenty of activists whose actions have enhanced not just their funds' portfolios, but those of passive, minority shareholders. They've forced companies to make positive changes -- to restructure, elect new board members, and get back on track toward healthier operations. Then again, others end up like J.C. Penney -- a seemingly lost business, rich with legacy yet left crippled by boardroom drama. That leaves us -- the average consumers and investors -- with a pressing question: Are these megaphoned power players trying to effect change that will benefit all, the company included? Or are they just after results that will juice their own returns? The Age of Activism While many activist investors consider themselves to be molded in the image of a certain Omaha-based super-investor, many of today's hedge fund superstars have taken a very different approach to the craft of identifying mispriced securities. Like the old guard -- raiders like Carl Icahn and Nelson Peltz -- young guns such as Daniel Loeb and Bill Ackman take substantial positions in large public companies and demand change in an approach that is about as far from Warren Buffett's investor behavior as one can get. Their style can be best described as personality-driven activism. The practice is on the rise, too. According to FactSet, 2012 saw 21 activist campaigns in companies with market caps larger than $1 billion. In 2010, the number was 11. In 2003, there were four. While some passive shareholders may

Best Dow Dividend Companies To Own For 2014: Highpower International Inc (HPJ)

Highpower International, Inc., incorporated on January 3, 2006, is engaged in the production and sales of rechargeable nickel-metal hydride (Ni-MH) batteries, lithium batteries and battery systems. The Company also recycles scrap battery materials through outsourcing and resells the recycled materials to some of its customers. The Company�� wholly owned subsidiary is Hong Kong Highpower Technology Company Limited (HKHTC). HKHTC�� wholly owned subsidiaries Shenzhen Highpower Technology Company Limited (SZ Highpower), Highpower Energy Technology (Hui Zhou) Company Limited (HZ Highpower), Springpower Technology (Shenzhen) Company Limited (SZ Springpower) and Icon Energy System Company Limited (ICON) and SZ Highpower�� wholly owned subsidiary Ganzhou Highpower Technology Company Limited (Ganzhou Highpower).

The Company�� Ni-MH rechargeable batteries are solutions for many applications. The Company�� Ni-MH rechargeable batteries offer capacity and energy density. As a result, users can expect a longer time between charges and longer running time. The Company�� Ni-MH rechargeable batteries are available in both cylindrical and prismatic shapes. The Company produces Li-ion batteries and Li-polymer batteries with hundreds of different models and specifications. As of December 31 2011, the Company produced an average of 1,520,000 lithium battery units per month.

The Company�� batteries fall into two main categories, such as consumer batteries and industrial batteries. The Company�� consumer batteries category produces Ni-MH and lithium batteries, which offers power capacity, allowing for longer working time and shortened charging time during equivalent working periods. The Company produces A, AA and AAA sized batteries in blister packing, as well as chargers and battery packs. The Company�� industrial batteries are designed for electric bikes, power tools and electric toys. They are specifically designed for high-drain discharge applications.

The Comp! any competes with SANYO Electric Co., Ltd., Panasonic, BYD Company Ltd., GPI International, Ltd., GS Yuasa Corporation, Desay Corp., Coslight Group, Tianjin Lishen Battery Co. Ltd. and ATL.

Advisors' Opinion:

• [By Kyle Woodley]

  The short, sucky answer? A lot:

  Plans for a ��igafactory��meant to produce millions of electric-car batteries ginned up excitement, but also raised eyebrows. The Wall Street Journal reported on skepticism in the space — including from heads at Volkswagen (VLKAY) and battery maker Highpower International (HPJ). Now, even planned investment partner Panasonic (PC) now sounds iffy on the project, with company Kazuhiro Tsuga saying “the investment risk is definitely larger.” Not good. There also was Tesla�� direct sales snafu. New Jersey Gov. Chris Christie huffed and puffed and (on March 11) successfully blew down Tesla�� direct sales model, with the Motor Vehicle Commission approving a measure to enforce an already-existing ban on direct sales. On the flip side, Tesla has scored victories in New York and Ohio in the past month, and is making progress in Arizona (which has a little incentive on the board). Production of the Model X has been pushed further back, to 2015. Musk’s reasons — mostly having to do with focusing on bolstering Model S sales — are valid, but that doesn�� really soften the blow of a longer wait for the much-anticipated addition to Tesla�� line. To address the issue of battery fires in the Model S, TSLA added titanium shields and aluminum deflector plates to new vehicles and offered to install them for free in all its existing cars. Tesla�� margins are excellent, and there�� no hard number on the cost impact of the fix, but titanium ain�� cheap. This definitely isn�� going to add to Tesla�� bottom line. What Now?

  I won�� belabor you with my bullish position on TSLA stock, but if you want, you can see it here. In short, Musk is a genius; Tesla products are quality and appeal to (and are priced for) the all-important luxury segment; and just given size and scale, TSLA has oh-so-much room to grow.

Best Dow Dividend Companies To Own For 2014: Burlington Stores Inc (BURL)

Burlington Stores, Inc., incorporated on February 13, 2013, is a national off-price retailer of branded apparel, operating 503 stores, inclusive of an Internet store, in 44 states and Puerto Rico. The Company offers its merchandise using an Every Day Low Price (EDLP) model with savings up to 60-70% off department and specialty store regular prices. It provides its customers with a selection of fashionable branded product in women�� ready-to-wear apparel, menswear, youth apparel, baby products, footwear, accessories, home goods and coats. The Company merchandise from over 3,500 vendors, with a focus on nationally-recognized brands. This vendor breadth provides its customers with a treasure hunt experience of searching for great brands at great value.

The Company�� average store size is approximately 80,000 square feet, which is two to three times the size of its off-price competitors��stores. Its larger store size has allowed the Company to offer more categories and substantially more breadth in each product category than its off-price competitors and to establish ourselves as a destination for select categories, including coats, youth and baby, special-occasion dresses and men�� tailored apparel.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading UP
  Burlington Stores (NYSE: BURL) shares shot up 15.02 percent to $29.79 on Q4 results. Burlington Stores reported its Q4 earnings of $1.07 per share, versus analysts' estimates of $1.03 per share.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Burlington Stores (NYSE: BURL) shares shot up 11.91 percent to $28.99 on Q4 results. Burlington Stores reported its Q4 earnings of $1.07 per share, versus analysts' estimates of $1.03 per share.

• [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]

  Among the companies expected to actively trade in Thursday’s session are Burlington Stores Inc.(BURL), ConAgra Foods Inc.(CAG) and Guess Inc.(GES)

Best Dow Dividend Companies To Own For 2014: Dialog Semiconductor PLC (DLG)

Dialog Semiconductor Plc creates integrated, mixed signal integrated circuits (ICs), optimized for personal portable, short-range wireless, lighting, display and automotive applications. The Company operates in three business segments: Mobile Systems, Automotive and Industrial, and Connectivity. The Mobile Systems segment includes its power management and audio chips especially designed to meet the needs of the wireless systems markets and a range of advanced driver technologies for low power display applications - from Passive Matrix Organic Light Emitting Diodes (PMOLEDs), to electronic paper and Micro Electro-Mechanical Systems (MEMS) displays. The Automotive and Industrial segment consists of products, which address the safety, management and control of electronic systems in cars and for industrial applications. The Connectivity segment includes activities, such as short-range wireless, digital cordless and voice over Internet protocol (VoIP) technology. Advisors' Opinion:

• [By Corinne Gretler]

  Colruyt SA jumped the most in almost a year after reporting earnings that beat estimates. Direct Line Insurance Group Plc (DLG), the U.K.�� biggest home and motor insurer, rallied 3.8 percent after saying it will cut jobs. GSW Immobilien AG, Berlin�� largest residential landlord by market value, advanced 3.8 percent after saying both its chairman and chief executive officer will leave. Mining companies declined as metals fell.

• [By Jonathan Morgan]

  Direct Line (DLG) dropped 2.5 percent to 212.6 pence. RBS sold 300 million shares at 210 pence apiece in its third sale of a stake in the insurance company, according to a statement. The bank, which is majority owned by the U.K. government, reduced its holding in Direct Line by 20 percent to 28.5 percent. RBS slipped 1.3 percent to 364.1 pence.

Best Dow Dividend Companies To Own For 2014: IB Securities Joint Stock Co (VIX)

IB Securities Joint Stock Company, formerly XuanThanh Securities Joint Stock Company is a Vietnam-based company engaged in the provision of investment services. It provides securities brokerage services through multiple forms, such as VOpen, VSHM, VTrade, VPhone, VMobile and VSMS. The Company is also involved in securities trading, as well as the provision of investment advice, custody services and underwriting services. In addition, it provides financial services for corporate events, such as corporate restructurings, equitizations, stock listings, share auctions, mergers and acquisitions, equity offerings and bond offerings. Advisors' Opinion:

• [By Aubrey Pringle]

  The CBOE Volatility Index (VIX), the gauge of S&P 500 options prices known as the VIX, rose 1 percent to 14.53. The equity volatility gauge has tumbled 15 percent in September after rallying 26 percent in August, the biggest monthly gain since May 2012.